Glucokinase activators and methods of using same

Details Glucokinase activators and methods of using same Glucokinase activators and methods of using same

2008-07-25

2010-10-12

Anderson, Rebecca L (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S333500

Reexamination Certificate

active

07812048

ABSTRACT:
Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structurewhere Q isand R1, R2, R3, R4, R5, R6, R7and R8are as defined herein or a pharmaceutically acceptable salt thereof.A method for treating diabetes and related diseases employing the above compounds is also provided.

REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4261730 (1981-04-01), Bollinger et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6414002 (2002-07-01), Cheng et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6548481 (2003-04-01), Demuth et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6653314 (2003-11-01), Cheng et al.
patent: 2006/0167053 (2006-07-01), IIno et al.
patent: 3214227 (1983-10-01), None
patent: 0 221 025 (1987-05-01), None
patent: 0 142 146 (1988-08-01), None
patent: 1 177 791 (2002-02-01), None
patent: 1 690 863 (2006-08-01), None
patent: 2 596 393 (1986-04-01), None
patent: 2 205 837 (1988-12-01), None
patent: 2003 300875 (2003-10-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/43663 (1999-09-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/39077 (2000-07-01), None
patent: WO 00/69849 (2000-11-01), None
patent: WO01/05769 (2001-01-01), None
patent: WO03/035621 (2003-05-01), None
patent: WO03/037332 (2003-05-01), None
patent: WO 03/106427 (2003-12-01), None
patent: WO 2004076420 (2004-09-01), None
patent: WO 2004/099155 (2004-11-01), None
patent: WO2005/032493 (2005-04-01), None
patent: WO 2005/080359 (2005-09-01), None
patent: WO 2005/121110 (2005-12-01), None
patent: WO2006/112549 (2006-10-01), None
patent: WO2007/061923 (2007-05-01), None
Patani et al. Chem. Rev. 1996, 96, 3147-3176.
Wermuth, C. G. Molecular variations based on isosteric replacements. In the Practice of Medicinal Chemistry, Wermuth, C. G., Eds.; 1996; pp. 202-237.
Sheridan, R. P. J. Chem. Inf. Comput. Sci. 2002, 42, 103-108.
Rautio et al. Nature Reviews Drug Discovery 2008, 7, pp. 255-270.
Wang et al. Drug Delivery: Principles and Applications, 2005 John Wiley & Sons, Inc. Publication, Section 8.3, pp. 136-137.
Smith, D. A. Current Opinion in Drug Discovery & Development 2007, 10, 550-559.
Testa, B. Current Opinion in Chemical Biology 2009, 13, pp. 338-344.
Hadden, M.K. et al, “Cytotoxic small molecule dimmers and their inhibitory activity against human breast cancer cells”, Bioorganic & Medicinal Chemistry Letters, vol. 17, No. 18, 2007, pp. 5063-5067.
McKerrecher, D. et al., “Discovery synthesis and biological evaluation of novel glucokinase activators”, Bioorganic & Medicinal Chemistry Letters, vol. 15, No. 8, 2005, pp. 2103-2106.
Arbeeny, C. et al. “The Metabolic Syndrome: From Pathophysiology to Novel Treatment Strategies”, Curr. Med. Chem.—Imm. Endoc. & Metab. Agents, 1:1-24 (2001).
Ashworth et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitros of Deipeptidyl Peptidase IV”, Biog. & Med. Chem. Lett., vol. 6, No. 10, pp. 1163-1166, (1996).
Ashworth et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Biorg. & Med. Chem. Lett., vol. 6, No. 22, pp. 2745-2748, (1996).
Biller et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitor of Squalene Synthetase”, Amer. Chem. Soc., vol. 31, No. 10, pp. 1869-1871 (1988).
Biller et al., “Squalene Synthetase Inhibitors”, Curr. Pharm. Des, 2, pp. 1-40 (1996).
Bundgaard, H., Design of Prodrugs, Elsevier, 1985.
Bundgaard, H. et al., A Textbook of Drug Design and Development, Chapter 5, pp. 113-191 (Harwood Academic Publishers, 1991).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, Dept. Med. Chem. U of Utah, Table of Contents pp. 16, 17, 40-43, 48-51, Summary, (1987).
Corey, E. J. et al, “Application of Unreactive Analogs of Terpenoid Pyrophosphates of Studies of Multistep Biosynthesis. Demonstration That Presqualene Pyrophosphate' is Essential Intermediate on the Path to Squalene”, J. Amer. Chem. Soc. 98, pp. 1291-1293 (1976).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, vol. 5, No. 1, pp. 11-20 (1999).
Ford, E.S. et al., “Prevalance of the Metabolic Syndrome Among US Adults”, J. Am. Med. Assoc., 287:356-359 (2002).
Fyfe, M.C. et al., “Glucokinase Activator PSN-GK1 Displays Enhanced Antihyperglycaemic and Insulinotropic Actions”, Diabetologia, 50:1277 (2007).
Ghiselli, G., “The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipdemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein”, Cardiovasc. Drug Rev. 16(1):16-30(1998).
Green, T.W. et al., Protecting Groups in Organic Synthesis, 1999.
Hara, S., “Ileal Na+/bile acid Contransporter Inhibitors”, Drugs of the Future, 24(4), pp. 425-430 (1999).
Hertzog, D.L., “Recent advances in the cannabinoids”, Expert. Opin. Ther. Patents, 14:1435-1452 (2004).
Hughes, T.E. et al., “(1-[[[2-[(5-Cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2- cyano-(S)-pyrrolidine), a Slow-Binding Inhibitor of Dipeptidyl Peptidase IV”, Biochem. 38, pp. 11597-11603 (1999).
Krause, B.R. et al. “ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals”, Inflammation: Mediators and Pathways, CRC Press Inc, publ., Ruffolo, Jr., R.R. et al., eds., pp. 173-198 (1995).
Lange, A.J. et al., “Expression and site-directed mutagenesis of hepatic glucokinase”, Biochem., J., 277:159-163 (1991).
Li, H. et al., “3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT): A new coupling reagent with remarkable resistance to race

Affiliated with

Also associated with

Rating

Glucokinase activators and methods of using same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glucokinase activators and methods of using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucokinase activators and methods of using same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4242324